Navigation Links
Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
Date:9/23/2009

DURHAM, N.C., Sept. 23 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received approval from Israel's Ministry of Health to begin a Phase II-b, dose escalation, clinical trial in that country for use of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

"This approval from the Israeli Ministry of Health means that we can begin enrolling patients in a second country with a first class health care system," said Chris Stern, company chairman and CEO. "We hope this trial can provide data to show that Oxycyte is of invaluable importance in improving the outcome of patients, both civilian and military, with severe TBI. It is our goal to finally prove that there is a safe and effective treatment for this devastating injury."

The clinical trial with four centers in Israel is part of a larger study that also includes seven trial centers in Switzerland. The company has named the 128 patient study "Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury" or "STOP TBI."

The dose escalation studies will focus on finding the lowest dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte would start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg for subsequent patient cohorts. Escalation of dose will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the start of a Phase II for Oxycyte in TBI. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that a sufficient number of patients will be enrolled in the trial nor any assurance of the outcomes. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
2. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
3. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
4. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
5. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
6. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
9. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
10. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
11. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an ... passed early toxicology and efficacy studies. The company is ... a specific protein, MAGE A, in an effort to ... After 4 weeks of treatment in ... very little toxicity in a full toxicology report of ...
(Date:3/27/2017)... 27, 2017 To mark the end of Save ... a leader in digital imaging solutions, will showcase Canon eye ... at New York,s Jacob Javits Center ... Month, sponsored by the American Optometric Association, is observed annually ... receiving comprehensive eye exams. In recognition of this observance, Canon ...
(Date:3/27/2017)... 27, 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s ... where cannabis is legal will generate $655 million in taxes on ... cannabis specific taxes, such as Washington State,s ... earned from state sales taxes that are applied on all retail ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... The respected dental team at ... teeth without the extensive time commitment and aesthetic disadvantages of traditional braces can ... A custom-designed series of virtually invisible aligners are created for each patient and ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to ... missing teeth can now have them placed by Dr. Manju Kejriwal, with or without ... Beam technology to increase the accuracy of each dental implant placement. The i-CAT CBCT ...
(Date:3/27/2017)... UK (PRWEB) , ... March 27, 2017 , ... ... and ability to gain site attention and engagement over the household brands of ... webinar will discuss how partnering with the right outsourcing payments provider ...
(Date:3/27/2017)... ... March 27, 2017 , ... A study by the ... and his colleague, Sudeep Roy, MD, was recently published in the American Journal ... in Rhytidectomy” details Drs. Buckingham and Roy’s study on the use of Electro Lube ...
(Date:3/27/2017)... ... ... Buzzies parent company, The TouchPoint Solution’s CEO and co-founder, Vicki Mayo, was recently ... Mayo will present her pitch about the lifestyle wearable devices, Buzzies live ... ignites bold ideas by providing women access to the tools, training and networks needed ...
Breaking Medicine News(10 mins):